Cardiovascular risks in Asian HIV-infected patients receiving boosted- protease inhibitor-based antiretroviral treatment

Sakaewan Ounjaijean; Kanokwan Kulprachakarn; Linda Aurpibul; Quanhathai Kaewpoowat; Kongsak Boonyapranai; Romanee Chaiwarith; Supapong Arwon; Khuanchai Supparatpinyo; Kittipan Rerkasem

doi:10.3855/jidc.12864

Back

Cardiovascular risks in Asian HIV-infected patients receiving boosted- protease inhibitor-based antiretroviral treatment

Journal article

Open access

Peer reviewed

Cardiovascular risks in Asian HIV-infected patients receiving boosted- protease inhibitor-based antiretroviral treatment

Sakaewan Ounjaijean, Kanokwan Kulprachakarn, Linda Aurpibul, Quanhathai Kaewpoowat, Kongsak Boonyapranai, Romanee Chaiwarith, Supapong Arwon, Khuanchai Supparatpinyo and Kittipan Rerkasem

Journal of infection in developing countries, Vol.15(2), pp.289-296

02/01/2021

DOI: 10.3855/jidc.12864

PMID: 33690213

Files and links (1)

url

https://doi.org/10.3855/jidc.12864View

Published (Version of record) Open Access

Abstract

Introduction: Increased risk of cardiovascular disease in HIV-infected patients was tought to be the cause of multiple mechanistic factors, which changing the HIV care landscape. Antiretroviral therapy (ART), especially protease inhibitors (PI), is one of common HIV treatments that may have some association with this. The mechanism of PI in comparison to other regimens, however, are not clearly understood. Methodology: Age-and gender-match HIV-infected patients treated with either boosted-PI-based regimen (boosted-PI group, N=30) or NNRTIbased ART (non-PI group, N = 30) were recruited for this cross-sectional study. Parameters determined cardiovascular risks, inflammation, endothelial function, and bone metabolic function were evaluated. Results: Compared with non-PI, patients in the boosted-PI group had more evidence of dyslipidemia. No statistical difference in the prevalence of subclinical atherosclerosis was found between the two groups. Circulating levels of inflammatory markers, C-reactive protein (CRP) (5.4?9.1 vs. 14.9 ? 19.4 mg/L, p = 0.019) and lectin-liked oxidized lipoprotein receptor-1 (LOX-1) (387 ? 299 vs. 554 ? 324 pg/mL, p = 0.042) were lower in boosted-PI group. Contrastingly, Vascular adhesion molecules-1 (VCAM-1) (160.2 ? 80.0 vs. 147.8 ? 66.3 ng/mL, p = 0.010), and osteoprotegerin (OPG) (153.7 ? 57.1 vs. 126.4 ? 35.8, p = 0.031) were higher. After adjustment in the multivariate analysis, PI treatment is the only independent parameter associated with the changes of CRP, LOX-1, VCAM-1, and OPG. Subgroup analysis showed that ARV treatment effects differed among participant having dyslipidemia. Conclusions: The major mechanism in which PI-mediated was triggering atherogenesis could be through alteration of lipid metabolism and endothelial function, but no evidence of accelerated pro-inflammatory response was attested.

Infectious Diseases

Life Sciences & Biomedicine

Science & Technology

Details

Title: Subtitle: Cardiovascular risks in Asian HIV-infected patients receiving boosted- protease inhibitor-based antiretroviral treatment
Creators: Sakaewan Ounjaijean - Chiang Mai University
Kanokwan Kulprachakarn - Chiang Mai University
Linda Aurpibul - Chiang Mai University
Quanhathai Kaewpoowat - Chiang Mai University
Kongsak Boonyapranai - Chiang Mai University
Romanee Chaiwarith - Chiang Mai University
Supapong Arwon - Chiang Mai University
Khuanchai Supparatpinyo - Chiang Mai University
Kittipan Rerkasem - Chiang Mai University
Resource Type: Journal article
Publication Details: Journal of infection in developing countries, Vol.15(2), pp.289-296
DOI: 10.3855/jidc.12864
PMID: 33690213
NLM abbreviation: J Infect Dev Ctries
ISSN: 1972-2680
eISSN: 1972-2680
Publisher: J Infection Developing Countries
Number of pages: 8
Grant note: Chiang Mai University
Language: English
Date published: 02/01/2021
Academic Unit: Internal Medicine
Record Identifier: 9984359829902771

Metrics

13 Record Views

6 Times Cited - Web of Science